In a recent Bayesian adaptive trial, investigators examined whether intravaginal magnesium sulfate could accelerate labor more effectively than the commonly used intravenous dexamethasone and standard care.
Design of the three‑arm study
The randomized controlled trial enrolled 150 first‑time mothers who were in the latent phase of labor. Participants were assigned to receive one of three interventions: a local dose of magnesium sulfate, a systemic dose of dexamethasone, or usual care without medication.
Primary outcomes focused on the duration of labor and changes in the Bishop score, which gauges cervical readiness. The team also recorded neonatal Apgar scores and any safety concerns for mothers or babies.
Because the Bishop score reflects cervical dilation, effacement, and consistency, its rapid improvement serves as a surrogate marker for the onset of active labor.
Magnesium sulfate shortens both latent and active phases
Both active treatments improved the Bishop score within six hours compared with the control group, indicating that cervical ripening occurred faster. The local magnesium approach cut the latent phase by an average of 3.0 hours, while dexamethasone reduced it by 1.8 hours.
Read Also: Finger-cuff blood pressure monitors questioned by new study
In the active phase, the compound shortened labor by roughly 2.0 hours versus about 1.1 hours for the steroid.
All newborns received Apgar scores of 8 or higher.
These uniformly high scores indicate that accelerated cervical ripening did not compromise immediate neonatal vitality.
No adverse events were reported for mothers or infants, suggesting a favorable safety profile for the vaginal route.
Implications for clinical practice
The data suggest that a local agent that works faster and avoids systemic exposure could be a practical alternative, especially when steroids pose a risk. If a medication can achieve cervical ripening without influencing glucose levels or immune function, clinicians might have a safer tool for patients who are diabetic, immunocompromised, or otherwise vulnerable to steroid side effects.
Read Also: Breastfeeding tied to healthier postpartum lipid levels
This advantage is especially relevant for women with pre‑existing metabolic disorders.
This trial illustrates how a targeted, tissue‑level intervention may reshape standard obstetric practice. By limiting absorption to the cervix, the agent reduces the chance of systemic complications that are sometimes seen with hormonal therapies.
Safety profile and next steps
The study highlighted the safety of the intravaginal route. Magnesium’s dual action—drawing water into cervical tissue and blocking calcium channels—appears to remodel the cervix locally while limiting systemic absorption. In contrast, dexamethasone works through hormonal pathways that can trigger hyperglycemia and suppress immunity.
Authors note that the trial was conducted at a single center, which limits how broadly the findings can be applied. Future multicenter research should examine long‑term neonatal outcomes, cost considerations, and how magnesium compares with prostaglandins or oxytocin.
Until larger studies confirm these results, clinicians may consider intravaginal magnesium sulfate for patients who cannot tolerate corticosteroids, while still keeping dexamethasone as an option when vaginal administration is not feasible.
